I am buying more stock today. Frankly I don't care what the
I am buying more stock today. Frankly I don't care what the share price is in the near future, since it is going to be vastly higher when we get news on any of the major developments we could see at any time, like:
Kevetrin -- more data, or another clinical trial starting, or another orphan drug designation for another disease, or receiving the grant that they applied for, for pancreatic cancer;
Brilacidin-OM -- preliminary human trial data. Please note that the claims made elsewhere that animal testing on hamsters supposedly is not indicative of success have been refuted well earlier today on this site.
Brilacidin-ABSSSI -- updates on clinical trial commencement (could be Phase 2/3)
Prurisol -- preliminary trial data
Rosen lawsuit/Mako: settlement (them paying CTIX), other legal stuff, perp walks of criminal shorts -- who knows
Other possible things:
Joint venture or research with another company
New clinical trial funded not by CTIX
New Board of Director appointments of well-known, well-connected people
or any number of other things that could happen….
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding the Impact of the SAVE Act on Expats As U.S. expats grapple with the complexities of taxation and representation, recent developments surrounding the SAVE Act prompt a crucial conversation. MyExpatTaxes, a leader in providing tax services to Americans abroad, has brought attention to the implications of this bill for millions of U.S. citizens living outside...
Continue Reading
U.K. Stock Market Overview The U.K. stock market closed on a positive note, showing promising signs across various indices. This is an encouraging moment for investors, particularly as shares from major sectors like mining, automobiles, and beverages have played a significant role in this upward trend. Insights into Sector Performance Recent analysis reveals that the...
Continue Reading
Key Presentation by Outlook Therapeutics at Upcoming Webinar Outlook Therapeutics, Inc. (NASDAQ: OTLK), a notable biopharmaceutical company known for its innovative approach in treating retinal diseases, has exciting news to share. The company has achieved remarkable milestones in the healthcare sector, particularly with its ophthalmic formulation of bevacizumab, a...
Continue Reading
Anglo American's Strategic Sale of Coal Portfolio Anglo American has made a significant decision to divest its Australian steelmaking coal portfolio, selling it to Peabody Energy for a total consideration of up to $3.8 billion. This transaction is part of Anglo American's broader strategy to pivot towards more sustainable and future-facing commodities. Details of the...
Continue Reading
Flow Traders Review of Trading Environment for Q1 2025 Welcome to the summary of Flow Traders' recent insights as presented by Eric Pan, the Head of Investor Relations. During the pre-close call for the first quarter of 2025, significant trends and data points were discussed that shape our understanding of the financial markets today. Insightful data was shared that not...
Continue Reading